Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (269)	3/10/2000 11:50:00 AM
From: tuck	Respond to of 423

Guten Morgen, Jeffrey & Gang, What a difference a letter makes, eh Jeffrey? Welcome to everybody that's found us so far. It'll be good to have some more heads on the thread, if each person kicks in a little. Y'all must have stocks that you're thinking about acting on soon. Share your knowledge, and we'll share ours. We check each others thinking and T/A, come to consensus, stick it on our watch list, and trade according to our individual styles. Ideally, we present our case with one post. Sometimes I get busy and can only post the most immediately important factors. If someone wants to pick up the ball in these cases, be my guest. Often rapid research is called for, and having a few people pulling together can really help. We can divvy up the work load among those interested in a particular pick. Allow me to finish with BMET, a case in point. I only saw the possibility of it hitting that 27 bottom three days ago, and folks unfamiliar with it probably couldn't get up to speed, but I didn't have time to flesh it out in a concise convincing way. ANyhow, I called this one on a value and technical basis. Undervalued, oversold, and clearly manipulated to pick up blocks in the 27s. BMET has not had the same sales growth as its peers, but it has a strong balance sheet and better margins. Price targets recently announced are in the $45 range. This is not one of our screamers, but not much downside from here, either. They have a lot of orthopedic products and are spending a lot on R&D; they are showing steady growth across all product lines, especially their spinal products. yahoo.marketguide.com Earnings and CC next week (3/14, I believe). They tend to surprise slightly to the upside. My guess is that y'all have missed your chance for the biggest bucks here, as it has made ~1/3 of it's move up the trading range, and I expect it to run up a bit more into earnings -- to 35 if the Open Interest Theory holds -- and then stall unless they're awfully good. If they're solid, up a little next week after a couple of days of post earnings consolidation. Still, a good play for the low risk, longer term types here. Good vehicle for covered call writing/put sales, one of my favorite techniques when the market is being strange. Cheers, Tuck

To: BRAVEHEART who wrote (269)	3/10/2000 2:51:00 PM
From: tuck	Read Replies (1) \| Respond to of 423

Jeffrey, Alert! Calling in the troops for DD on possible conversion rally . . . Watching the NEOP conversion rally has tuned me into certain things. Check out LOR. quote.yahoo.com Company has made good fundamental progress in executing business plan, though it has come a little slower than hoped WRT GSTRF. A production glitch & and slight delays in opening gateways for GSTRF have hammered both stocks. LOR is now getting hammered some more because LMT is getting ready to divest shares of LOR (that it got from converting preferred) due to antitrust/regulatory requirements arising from another LMT deal. Some 13.5% of the outstanding. The stock is near lows and analysts have downgraded it. Technically way oversold, but maybe not yet bottomed. LOR is withholding news, just like NEOP did: Message 13154255 I smell a conversion rally coming. Rocket Scientist has served up a clue. It is time to dig deeper. Disclosure: long in a small sold put position and considering adding here. I need help calling the entry here. It is close. LOR is valued at ~$9/share w/o GSTRF (per sum of parts valuations done by several analysts and at least one LOR threadster). Looks awfully cheap, and could easily go to the twenties and beyond when nints of resolution on the above issues come. And that should be pretty soon, I would think a few weeks. Cheers, Tuck

To: BRAVEHEART who wrote (269)	3/12/2000 9:59:00 PM
From: RWReeves	Respond to of 423

Weakness in the CRO sector. I agree with your assessment of short term earnings disappointments in CROs especially QTRN, PRXL took its lumps earlier , had a nice dead cat made a few bucks on. Long term absolutely right, not only is all the money sloshing around going to mean more work for CRO's but more complex work like pharmaco-economics (cost benefit trials)that insurers are demanding and the administration is likely to embrace more and more to contain new RX costs. Rather than tie up $ in CRO longs (which I did earlier and got bored with) I've been buying calls. Took a bit of a spanking in them, but expect to make it back as well as go long when the market gets around to them. Same play in pharma last week paid off nicely. Other good CROs to consider KNDL, CVD, PPDI, CVGR. Each has it's charms, I expect KNDL to have the larger gains due to larger beta and seems very well run. BTW some interesting mergers afoot in genomics and CROs. RWR

To: BRAVEHEART who wrote (269)	3/12/2000 11:18:00 PM
From: tuck	Respond to of 423

Jeffrey, I see you were asking when QTRN next reported earnings. They just did it in late January (26th), so we have a good month and a half to come up with an earnings related play there. I have to admit, as someone who has geared his style to covered writing over the years, that picking for the these kinds of goals is a leap for me. I start posting on something I like, then realize it's probably only good for 25% in a month or two, like STAA and BCHE. Good enough for a covered writer, anemic to you. But I'll keep trying. Time to go price some options and enter my orders. Check y'all tomorrow. Cheers, Tuck